Amyloid-β-Derived Peptidomimetics Inhibits Tau Aggregation.

The aggregation of tau protein is one of the hallmarks
for Alzheimer’s disease, resulting in neurodegeneration. The
peptidomimetics strategy to prevent tau aggregation is more specific
over other small molecules. In the present study, we analyzed the effect
of amyloid-β-derived peptidomimetics for inhibiting heparin-induced
tau aggregation in vitro. These peptides and their derivatives were
known to prevent aggregation of amyloid-β. KLVFF is a hydrophobic
sequence of the pentapeptide that prevented tau aggregation as
observed by thioflavin S fluorescence, transmission electron micros�copy, and circular dichroism spectroscopy. P4 and P5 also prevented
assembly of tau into aggregates and formed short fibrils. The β-sheet
breaker LPFFD was however ineffective in preventing tau aggregation.
The peptides further demonstrated reversal of tau-induced cytotoxicity
in a dose-dependent manner. Our results suggested that these peptides
can also be used to inhibit tau aggregation and also, toxicity induced by tau could be considered as potential molecules that have an
effect on tau as well as amyloid-β